Photo of David John Kuter, MD,Dphil

David John Kuter, MD,Dphil

  • Director, Center for Hematology


Accepting New Patients

Request a patient consultation Request a second opinion


My passion for hematology is based on my belief that scientific concepts can be usually applied at the bedside to provide patients with personalized, attentive care. But when science fails, a compassionate and soothing word may be equally helpful.




Centers & Specialties

Cancer Center

Clinical Interests
  • Platelet Disorders
  • Thrombosis and hemostasis
  • Polycythemia vera
  • Thrombocytopenia
  • Essential thrombocytosis
  • Myeloproliferative diseases
  • Coagulation disorders
  • Anticoagulation
  • Anemia
  • Gaucher's disease
  • Chronic myeloid leukemia
  • Hemochromatosis
  • Hematology
  • Monoclonal gammopathy of unknown significance
  • Myelofibrosis
Medical Education
  • MD, Harvard Medical School
  • D.Phil., Oxford University
  • Residency, Massachusetts General Hospital
  • Fellowship, Massachusetts General Hospital
Board Certifications
  • Hematology
  • Internal Medicine
  • Medical Oncology
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Centene/Celticare
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • Medicaid
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
Patient Age Group

Edit Profile


Dr. David Kuter is Director of Clinical Hematology at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. He received his undergraduate degree from Harvard College and his D. Phil. in Biochemistry while a Rhodes Scholar at Oxford University, before obtaining his medical degree from Harvard Medical School. Dr. Kuter divides his time between medical education of fellows and medical students, clinical care of patients with a wide range of hematological disorders, and clinical research of thrombopoietic agents. His basic science group was one of the labs that discovered thrombopoietin and his clinical research group carried out seminal studies using thrombopoietic agents in transfusion medicine and immune thrombocytopenia (ITP).  Dr Kuter is recipient of a number of awards, including the Irving London Teaching Award at Harvard Medical School, the Alfred Kranes Teaching Award at the Massachusetts General Hospital, the Douglas Family Foundation Prize for Research (2008 and 2010) at Massachusetts General Hospital, the Jane Green Memorial Prize for Teaching at the Massachusetts General Hospital, and the 2013 Earnest Beutler Award from the American Society of Hematology.  He has given over 500 invited lectures in over 50 countries and served as Visiting Professor in Beijing, Sydney, Tokyo, London, Durham, and New Haven.  Dr Kuter has authored or co-authored over 300 articles published in international peer-reviewed journals such as The Lancet, The New England Journal of Medicine and Blood.

Edit Profile

Research & Publications

Research Summary
Current areas of ongoing research:
  1. Hereditary hemorrhagic telangiectasis (HHT): NIH sponsored grant to assess effect of pamolidomide to reduce bleeding in patients with HHT.
  2. Immune thrombocytopenia (ITP): NIH sponsored grant to assess effect of addition of mycophenolyate to standard of care for patients with ITP.
  3. Heparin-induced thrombocytopepenia (HIT): lead in 17 center NIH-sponsored study of the natural history and treatment of HIT
  4. Polycythemia vera (P.vera): Incyte Corp study (Reveal Study) to assess the natural history, treatment and quality of life of patients with P. vera.
  5. ITP: Ph 1 study using anti-CD40 ligand antibody (BMS sponsor) to reduce the rate of thrombocytopenia in patients with ITP
  6. ITP: Ph 1 study assessing the use of Staph protein A (Protalix, Inc) in the treatment of ITP
  7. ITP: assessment of patients with ITP treated with TPO receptor agonists--effect on longterm remission
  8. ITP: assessment of TPO receptor agonists in raising the platelet count of thrombocytopenic patients about to have surgery
  9. ITP: study of platelet function in patients with ITP after treatment with romiplostim
  10. Autoimmune hemolytic anemia (AIHA): creator and major site for international registry for patients with this disorder.
Selected peer-reviewed publications (of over 300)
  • Kuter DJ, Beeler D, Rosenberg RD. The purification and characterization of megapoietin: a megakaryocyte growth promoting protein. Proc Natl Acad Sci 1994;91:11104-11108.
  • Kuter DJ, et al. Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology. Humana Press, New York, 1997.
  • Murphy MJ, Kuter DJ, Eds. Thrombopoietin: From Molecule to Medicine. AlphaMed Press, Miamisburg, OH, 1998.
  • Bussel J, Kuter DJ, George J, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J,Wasser J, Wiznitzer I, Kelly R, Chen CF, Nichol J. AMG 531, a thrombopoiesis-stimulating protein, for ITP. New Engl J Med 2006;355:1672-1681.
  • Kuter DJ, et al. Randomized, controlled, 6-month evaluation of AMG531 in patients with chronic immune thrombocytopenic purpura. Lancet 2008;371:395-403.
  • Kuter DJ et al. Romiplostim or standard of care in patients with immune thrombocytopenia. NEJM 2010;363:1889-1899.

Edit Profile

News & Events


55 Fruit Street
Boston MA, 02114-2696
Phone: 617-724-4000617-726-8033
Fax: 617-724-6801

Edit Profile

Back to Top